Women of childbearing potential and male participants must agree to practice adequate contraception while on study and for at least  months following the last dose of radiation therapy (RT) and for at least  days following the last dose of sorafenib (whichever is later)
Women of childbearing potential and male participants who are sexually active must practice adequate contraception during treatment and for  weeks following treatment
Women of childbearing potential and male participants agree to practice adequate contraception
Women of childbearing potential and male participants who are sexually active must practice adequate contraception during treatment and for  weeks following treatment
Women of childbearing potential and male participants must practice adequate contraception
Women of childbearing potential and male participants must practice adequate contraception
Women of childbearing potential and male participants must practice adequate contraception
Women of childbearing potential and male participants must practice adequate contraception
Patients of childbearing potential (male or female) must practice adequate contraception
Women of childbearing potential and male participants must practice adequate contraception
Women of childbearing potential and male participants must agree to practice adequate contraception
Women of childbearing potential and male participants must practice adequate contraception
Patients of childbearing potential must practice appropriate contraception
Serum pregnancy test for female patients of childbearing potential, =<  hours prior to study entry; women of childbearing potential and male participants must practice adequate contraception
Is pregnant; women of childbearing potential and male participants unwilling to practice adequate contraception
Women of childbearing potential and male subjects must practice adequate contraception
Women of childbearing potential and male participants must practice adequate contraception throughout the study
Women of childbearing potential and male participants must practice adequate contraception during protocol treatment and for at least  months following treatment
Women of childbearing potential and male participants must agree to practice adequate contraception during therapy
Women of childbearing potential and male participants who are sexually active must agree to practice adequate contraception during treatment and for  months post-treatment
Women of childbearing potential and sexually active male participants must agree to practice adequate contraception while on study and for at least  days following the last dose of chemotherapy or trastuzumab
Women of childbearing potential and male participants must practice adequate contraception
Serum pregnancy test for female patients of childbearing potential, =<  hours prior to study entry; women of childbearing potential and male participants must practice adequate contraception
Women of childbearing potential and male participants must practice adequate contraception
Women of childbearing potential and male participants must agree to use adequate contraception throughout the study and for up to  days after study treatment
Women of childbearing potential and male participants must agree to practice adequate means of birth control throughout their participation in the study and for  months after their last treatment
Women of childbearing potential and male participants must practice adequate contraception
Women of childbearing potential and male participants must practice adequate contraception
Patients of childbearing potential (male or female) must practice adequate contraception due to possible harmful effects of radiation and chemotherapy on an unborn child
Women of childbearing potential and male participants who are sexually active must practice adequate contraception during treatment and for  weeks following treatment
Women of childbearing potential and male participants must agree to use adequate contraception for the course of the study